 Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC NASDAQ:TLSA LON:TILS, which it started covering in April this year, repeating its valuation of US7.50 per ADR share, compared to a current price of US2.37. It comes after Tiziana announced, on May 25, it had begun treating a first patient with secondary progressive multiple sclerosis SPMS in a trial using nasally administered Foralumab - its fully-human anti-CD3 monoclonal antibody. 